Bio­gen makes a buy­out deal, but it’s not the big one you’ve been wait­ing for

The cat­a­lyst junkies have been buzzing for days about the pos­si­bil­i­ty that Bio­gen would use its Q4 re­port Thurs­day to fire off a long an­tic­i­pat­ed trans­for­ma­tion­al deal. They got a deal to­day, but it was more of a care­ful seed move than a mar­ket ground­break­er.

Bio­gen is pay­ing $10 mil­lion up­front to buy the XPO1 in­hibitor KPT-350 from Karyopharm $KP­TI. The drug is de­signed to guard against neu­ro­tox­i­c­i­ty and in­flam­ma­tion in the brain, which could pro­vide some help for the neu­rode­gen­er­a­tive­ly fo­cused Bio­gen’s $BI­I­IB pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER